Conference Coverage
about 13 hours ago
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026Trending on the Eye Care Network
1
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
2
Oku Digital Health launches from Topcon to link eye care, primary care
3
EURETINA 2026: Optogenetic therapy MCO-010 aims to restore vision in advanced macular disease
4
EURETINA 2026: Eyestem interim Phase 2 results for clinical study of Eyecyte-RPE for GA secondary to dry AMD
5
EURETINA 2026: Duravyu misses LUGANO endpoint but cuts treatment burden by 42%
Latest News
Oct 07, 2026 | Commentary
Wilmer's new glaucoma chief Thomas V. Johnson III on his vision
Eyes on September 2026: ESCRS insights, gene therapy wins, and the push to treat myopia as a disease
Oct 07, 2026
Real-world VOYAGER data on faricimab in nAMD, DME, RVO at EURETINA 2026
Oct 07, 2026
Women's Health: Seeing lung cancer through the eyes of patients
Oct 06, 2026
2026 Nobel Prize in Physiology or Medicine awarded for optogenetics discovery
Oct 05, 2026
Advertisement
Shorts
0:35
Nimesh Patel, MD, on why pediatric myopia is more than a glasses problem
a day ago
0:45
EURETINA 2026: Predicting treatment and prognosis in central serous chorioretinopathy
2 days ago
1:04
EURTINA 2026: Mapping patients with inherited retinal disease to unlock new therapies
4 days ago
0:54
Euretina 2026: AI's biggest potential lies in retinal imaging, not surgery (yet)
6 days ago
0:49
Closing the gap between retina innovation and patient care
13 days ago
0:46
ESCRS 2026: Why aceclidine drops are a task-specific solution
14 days ago
1:09
ESCRS 2026: Fitting light therapy into the cataract surgery workflow
15 days ago
0:55
Stop ignoring your eyelids: the hidden risk of dry eyes
17 days ago
0:56
ESCRS 2026: Why retinal measurements can be wrong
19 days ago
0:39
ESCRS 2026: What makes a good candidate for aceclidine drops?
21 days ago
Digital Edition
Ophthalmology Times
Sequencing IOL choice by eye can ease patient decision paralysis.
Ophthalmology Times
Concurrent exudative disease, early intervention, and a rare masquerader complicate the classic picture of geographic atrophy.
Ophthalmology Times
Epithelial basement membrane dystrophy can affect premium IOL outcomes.
Ophthalmology Times
A checklist could help keep patients with geographic atrophy on track.
Ophthalmology Times
Influence on effective lens position in cataract and lens-based surgery.
Ophthalmology Times
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Ophthalmology Times
Waste, cost, and carbon are converging to reshape how cataract centers choose instruments.
Ophthalmology Times
Ultra-widefield imaging reveals early retinal risk in pediatric patients.
Ophthalmology Times
Two cases illustrate how recognizing and treating Demodex can change surgical outcomes and resolve chronic dry eye disease.
Ophthalmology Times
Learning Brazilian Portuguese boosts brain resilience and may delay dementia symptoms, but a humorous lesson highlights the realities of health care paperwork and waiting rooms.
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
At EURETINA 2026, Roger Goldberg, MD, MBA, explains why EYP-1901 missed LUGANO's primary endpoint despite matched anatomy, clean safety and a 42% cut in treatment burden.
Cataract original papers on intracameral antibiotics and IOL power, a guideline-based case symposium, and ocular surface sessions headline AAO 2026.
Ashish Sharma, MD, on what real-world data show about switching and long-term outcomes with retinal biosimilars.
• The American Academy of Ophthalmology 2026 annual meeting is set for October 9-12 in New Orleans.
Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026.
Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.
Women’s systemic and ocular health associated with pregnancy is a focus at EURETINA 2026 in Vienna.
Three EURETINA 2026 e-posters examine OCT/OCTA biomarkers and real-world switching to faricimab or aflibercept 8 mg in nAMD.
Three studies use OCT and OCTA to track AMD treatment response, flag diabetic retinopathy before oedema and confirm ocular toxoplasmosis.
Inherited metabolic diseases affect the retina even before the systemic diagnosis is established.
Advertisement
Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and neurodegenerative disease.
An industry symposium on intravitreal 4D-150 and a course on subretinal delivery lead gene therapy content at EURETINA 2026, alongside IRD courses and trial readouts.
Nimesh Patel, MD, urges the FDA to reconsider SYD-101 as pediatric myopia drives earlier retinal damage in US children.
Sequencing IOL choice by eye can ease patient decision paralysis.
Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.
Advertisement
Advertisement